Stockreport

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright [Yahoo! Finance]

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects a [Read more]